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BACKGROUND
Ibrutinib has been approved by the Food and Drug Administration for the treat-
ment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but 
has not been compared with chemoimmunotherapy. We conducted a phase 3 trial 
to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, 
relative to chemoimmunotherapy.
METHODS
Patients 65 years of age or older who had untreated CLL were randomly assigned 
to receive bendamustine plus rituximab, ibrutinib, or ibrutinib plus rituximab. The 
primary end point was progression-free survival. The Alliance Data and Safety Moni-
toring Board made the decision to release the data after the protocol-specified ef-
ficacy threshold had been met.
RESULTS
A total of 183 patients were assigned to receive bendamustine plus rituximab, 182 
to receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median progression-
free survival was reached only with bendamustine plus rituximab. The estimated 
percentage of patients with progression-free survival at 2 years was 74% with benda-
mustine plus rituximab and was higher with ibrutinib alone (87%; hazard ratio for 
disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 0.58; 
P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 0.25 
to 0.59; P<0.001). There was no significant difference between the ibrutinib-plus-
rituximab group and the ibrutinib group with regard to progression-free survival 
(hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P = 0.49). With a median follow-up of 38 
months, there was no significant difference among the three treatment groups with 
regard to overall survival. The rate of grade 3, 4, or 5 hematologic adverse events 
was higher with bendamustine plus rituximab (61%) than with ibrutinib or ibrutinib 
plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 non-
hematologic adverse events was lower with bendamustine plus rituximab (63%) than 
with the ibrutinib-containing regimens (74% with each regimen).
CONCLUSIONS
Among older patients with untreated CLL, treatment with ibrutinib was superior to 
treatment with bendamustine plus rituximab with regard to progression-free sur-
vival. There was no significant difference between ibrutinib and ibrutinib plus ritux-
imab with regard to progression-free survival. (Funded by the National Cancer Insti-
tute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872.)
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Chronic lymphocytic leukemia (CLL) is the most prevalent form of leukemia in adults and is incurable in most cases. In-
vestigation into the pathogenesis of CLL has 
implicated B-cell receptor signaling as a central 
driver, and targeting of this pathway through in-
hibition of Bruton’s tyrosine kinase (BTK) has de-
layed and prevented the onset of disease in experi-
mental systems.1,2
Among patients 65 years of age or older, chemo-
immunotherapy with either chlorambucil plus 
obinutuzumab3 or bendamustine plus rituximab4 
has shown efficacy and represents standard treat-
ment, although the approach is often modified. 
Chemoimmunotherapy is associated with toxic ef-
fects in many patients, and the risk of toxic effects 
increases with age. Thus, a targeted oral therapy 
that is effective and is associated with an accept-
able toxic-effect profile could be of value in pa-
tients with CLL.
Ibrutinib is an irreversible BTK inhibitor 
that abrogates CLL-related cell signaling, adhe-
sion, proliferation, and homing in vitro and in 
vivo.5-11 Among patients with CLL, treatment with 
single-agent ibrutinib led to a median progres-
sion-free survival of 52 months among those 
who had relapsed or refractory disease12; among 
those who received ibrutinib as initial treatment, 
the percentage of patients who were alive and 
free from disease progression at 2 years was 
89%.13 Ibrutinib has been widely used as an ini-
tial treatment for CLL since 2016, when it was 
approved by the Food and Drug Administration 
and by the European Medicines Agency for this 
indication, on the basis of its superiority to 
chlorambucil.14 The benefit of ibrutinib relative 
to standard chemoimmunotherapy remains a criti-
cal consideration.
The addition of rituximab or other CD20 
antibodies to chemotherapy prolongs progres-
sion-free survival and overall survival,3,15 and such 
antibodies have been thought to be indispens-
able in the treatment of CLL. Whether the addi-
tion of rituximab to ibrutinib leads to increased 
efficacy is controversial. In this phase 3 trial 
(A041202), we address two main questions. First, 
among older patients with untreated CLL, is treat-
ment with ibrutinib or ibrutinib plus rituximab 
superior to treatment with bendamustine plus 
rituximab? Second, does the addition of ritux-
imab to single-agent ibrutinib lead to increased 
efficacy?
Me thods
Patients
Eligible patients were 65 years of age or older 
and had untreated CLL for which treatment was 
indicated, as defined by International Workshop 
on CLL (IWCLL) criteria.16 The IWCLL criteria and 
a full list of eligibility criteria are provided in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.
Trial Oversight
This phase 3 trial was coordinated by the Alliance 
for Clinical Trials in Oncology (Alliance) in col-
laboration with the National Cancer Institute Can-
cer Trials Support Unit and was approved by a 
central institutional review board, as well as local 
institutional review boards as required by partici-
pating institutions. The trial was conducted in 
accordance with the principles of the Declaration 
of Helsinki. The data were collected by the inves-
tigators and entered into an electronic database 
that was maintained by the Alliance Statistics and 
Data Center. To ensure data quality, a review of 
data was performed by the Alliance Statistics and 
Data Center and by the trial chairperson in accor-
dance with Alliance policies. The trial was 
monitored at least twice annually by the Alliance 
Data and Safety Monitoring Board, a standing 
committee that was composed of persons from 
inside and outside the Alliance. All the authors 
reviewed and approved the manuscript and vouch 
for the completeness and accuracy of the data and 
the fidelity of the trial to the protocol, available at 
NEJM.org. No one who is not an author contrib-
uted to authorship of the manuscript. The Na-
tional Cancer Institute was the trial sponsor and 
obtained ibrutinib under a cooperative research 
and development agreement with Pharmacyclics 
(a subsidiary of AbbVie). Pharmacyclics had no role 
in the design of the trial, collection or interpreta-
tion of the data, or authorship of the manuscript. 
Fluorescence in situ hybridization (FISH) probes 
were provided by Abbott Molecular and Leica Bio-
systems.
Evaluation, Randomization, and Treatment
Before each patient underwent randomization, a 
blood sample was submitted for central testing for 
methylation at the promoter region of the ZAP70 
gene (encoding zeta chain–associated protein ki-
nase 70 [ZAP70]).17 Unmethylated ZAP70 correlates 
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with expression of ZAP70, a finding that conveys 
a poor prognosis. Approximately 76% of CLL cells 
that express ZAP70 also contain unmutated IgVH 
(immunoglobulin variable heavy chain) genes, 
another predictor of poor prognosis. Sequencing 
of IgVH genes in CLL cells was not routinely per-
formed in this trial. The following risk factors for 
CLL were used for stratification: ZAP70 methyla-
tion status on central testing (unmethylated [<20%] 
vs. methylated [≥20%]), risk category according to 
modified Rai stage (intermediate vs. high),18 and 
status with regard to del(17p13.1) or del(11q22.3) 
on local FISH analysis (absent vs. present).
Patients were randomly assigned, in a 1:1:1 
ratio, to receive bendamustine plus rituximab, 
ibrutinib, or ibrutinib plus rituximab. A dynamic 
randomization method was used, with stratifi-
cation according to risk factors for CLL.19 Treat-
ment was administered in 28-day cycles. Benda-
mustine-plus-rituximab therapy consisted of six 
cycles of bendamustine (administered at a dose of 
90 mg per square meter of body-surface area on 
days 1 and 2 of each cycle) plus rituximab (admin-
istered at a dose of 375 mg per square meter on 
the day before day 1 of cycle 1 and then at a dose 
of 500 mg per square meter on day 1 of cycles 2 
through 6). At the investigator’s discretion, the 
cycle 1 dose of bendamustine could be 70 mg per 
square meter. Ibrutinib was administered at a dose 
of 420 mg daily until the patient had unacceptable 
toxic effects or disease progression. Ibrutinib-plus-
rituximab therapy consisted of ibrutinib (admin-
istered as described previously and given before 
rituximab on days when they were administered 
together) plus rituximab (administered at a dose 
of 375 mg per square meter weekly for 4 weeks 
starting on day 1 of cycle 2 and then on day 1 of 
cycles 3 through 6). Patients in the bendamustine-
plus-rituximab group who had disease progres-
sion could cross over to receive ibrutinib within 
1 year after progression. Details regarding treat-
ment, including instructions for dose delays and 
modifications, are provided in the Methods sec-
tion in the Supplementary Appendix.
End Points and Assessments
The primary end point was progression-free sur-
vival, which was defined as the time from the 
date of randomization until the earliest date on 
which disease progression (as defined by IWCLL 
criteria) or death from any cause was recorded. 
Data from patients who were alive and had not 
had disease progression were censored on the date 
of the last assessment. Data from patients who 
started a therapy for CLL that was not specified 
in the protocol or withdrew consent for further 
follow-up were also censored on the date of the 
last assessment.
A secondary end point was overall survival. 
Assessments of response and complete response 
were performed by means of computed tomogra-
phy (CT) and physical examination. A central 
assessment of minimal residual disease in bone 
marrow was performed at cycle 9 with the use of a 
standard flow-based assay, which is capable of 
detecting 1 tumor cell in 10,000 cells. An ad-
verse-event analysis was also performed.
For a correlative analysis, patients underwent 
a geriatric assessment and central laboratory stud-
ies before treatment. The geriatric assessment 
included an analysis of the score for activities of 
daily living (with scores ranging from 0 to 14 and 
higher scores indicating better performance) and 
of the number of coexisting conditions. Details 
regarding these assessments are provided in the 
Supplementary Appendix.
Statistical Analysis
For the comparison of ibrutinib with bendamus-
tine plus rituximab, we estimated that a sample 
of 332 patients, with an expected 159 events, 
would provide the trial with 90% power to detect 
a hazard ratio for disease progression or death of 
0.586 (corresponding to an estimated percentage 
of patients with progression-free survival at 2 years 
of 61% with bendamustine plus rituximab and 
75% with ibrutinib), at a one-sided significance 
level of 0.025 by a log-rank test. The same assump-
tions, sample, and power calculation applied for 
the comparison of ibrutinib plus rituximab with 
bendamustine plus rituximab. If ibrutinib and 
ibrutinib plus rituximab were each superior to 
bendamustine plus rituximab, then ibrutinib 
plus rituximab was to be compared with ibruti-
nib. For the comparison of ibrutinib plus ritux-
imab with ibrutinib, we estimated that a sample 
of 332 patients, with an expected 119 events, 
would provide the trial with 90% power to detect 
a hazard ratio of 0.57 (corresponding to an esti-
mated percentage of patients with progression-
free survival at 2 years of 75% with ibrutinib and 
85% with ibrutinib plus rituximab), at a one-
sided significance level of 0.05 by a log-rank 
test. Thus, the total planned sample was 498 
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patients who could be evaluated, or 166 patients 
per group.
For the comparisons of ibrutinib and ibrutinib 
plus rituximab with bendamustine plus ritux-
imab, three interim efficacy and futility analyses 
were planned. For the comparison of ibrutinib plus 
rituximab with ibrutinib, two interim efficacy 
and futility analyses were planned. In May 2018, 
the Alliance Data and Safety Monitoring Board 
made the decision to release these data on the 
basis of the results of the protocol-specified sec-
ond interim analysis for the comparisons of the 
two ibrutinib-containing regimens with benda-
mustine plus rituximab and the protocol-speci-
fied first interim analysis for the comparison of 
ibrutinib plus rituximab with ibrutinib.
In accordance with the protocol, the primary 
analysis of progression-free survival included all 
patients who underwent randomization except 
those who, after randomization, were determined 
to have not met the eligibility criteria at screening. 
P values for the primary analysis are one-sided. 
Secondary analyses included all patients who un-
derwent randomization, regardless of eligibility. 
P values for all secondary analyses are two-sided. 
Prespecified and exploratory subgroup analyses 
were also performed. All analyses were performed 
by the Alliance Statistics and Data Center with the 
use of SAS software, version 9.4. Data were locked 
for this analysis as of October 4, 2018.
R esult s
Patient Characteristics
From December 2013 to May 2016, a total of 644 
patients were preregistered and 547 were enrolled 
Figure 1. Screening, Randomization, and Analysis.
Of the 547 patients who underwent randomization, 23 (4%) were determined to have not met the eligibility criteria 
at screening and were excluded from the primary analysis, in accordance with the protocol. These patients were in‑
cluded in the intention‑to‑treat analysis.
547 Underwent randomization
(1:1:1)
644 Patients were screened for eligibility
97 Were excluded
52 Did not meet eligibility criteria
19 Were not enrolled owing to investigator decision
16 Were not enrolled owing to patient decision
10 Were not enrolled for other reasons
183 Were assigned to receive
bendamustine+rituximab
182 Were assigned to receive
ibrutinib+rituximab
176 Were included in primary analysis
7 Did not meet eligibility criteria
and were excluded
176 Were included in adverse-event
analysis
7 Did not begin treatment and
were excluded
183 Were included in secondary
analyses
178 Were included in primary analysis
4 Did not meet eligibility criteria
and were excluded
180 Were included in adverse-event
analysis
2 Did not begin treatment and
were excluded
182 Were included in secondary
analyses
170 Were included in primary analysis
12 Did not meet eligibility criteria
and were excluded
181 Were included in adverse-event
analysis
1 Did not begin treatment and
was excluded
182 Were included in secondary
analyses
182 Were assigned to receive
ibrutinib
30 Crossed over from
bendamustine+
rituximab to ibrutinib
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at 219 sites throughout the United States and 
Canada (Fig. 1, and see the Supplementary Ap-
pendix). Of the 547 patients who were enrolled in 
the trial, 183 were randomly assigned to receive 
bendamustine plus rituximab, 182 to receive 
ibrutinib, and 182 to receive ibrutinib plus ritux-
imab. The characteristics of the patients were 
typical of a population with untreated CLL (Ta-
ble 1, and Table S2 in the Supplementary Appen-
dix); the median age was 71 years (range, 65 to 
89), and 367 patients (67%) were men.
With regard to risk factors for CLL, 46% of the 
patients had intermediate-risk disease and 54% 
had high-risk disease according to modified Rai 
stage, 53% had ZAP70-unmethylated disease on 
central testing (with ZAP70-unmethylated disease 
status used as a surrogate for IgVH-unmutated 
disease status), and 27% had disease associated 
with the presence of del(17p13.1) or del(11q22.3) 
on local FISH analysis. A separate, central FISH 
analysis performed with the use of the hierarchi-
cal classification method established by Döhner 
et al.20 revealed the presence of del(17p13.1) in 
6% of the patients, del(11q22.3) in 19%, trisomy 
12 in 22%, and del(13q14.3) in 36%, as well as 
the absence of all these abnormalities in 17%. In 
addition, 29% of the patients had a complex karyo-
type, with at least three unrelated cytogenetic ab-
normalities as assessed by central review,21 and 
10% had a mutation in TP53 with a variant allele 
frequency of more than 10%. Of the 360 patients 
who underwent central sequencing of IgVH genes, 
Characteristic
All Patients 
(N = 547)
Bendamustine+ 
Rituximab 
(N = 183)
Ibrutinib 
(N = 182)
Ibrutinib+ 
Rituximab 
(N = 182) P Value*
Age — yr 0.53
Median 71 70 71 71
Range 65–89 65–86 65–89 65–86
Male sex — no. (%) 367 (67) 119 (65) 123 (68) 125 (69) 0.75
High‑risk disease according to modified Rai stage  
— no. (%)
296 (54) 99 (54) 99 (54) 98 (54) 0.99
ECOG performance‑status score — no. (%)† 0.06
0 271 (50) 98 (54) 87 (48) 86 (47)
1 259 (47) 75 (41) 90 (49) 94 (52)
2 17 (3) 10 (5) 5 (3) 2 (1)
FISH analysis according to hierarchical classification 
of Döhner et al. — no./total no. (%)‡
0.99
Del(17p13.1) 34/542 (6) 14/181 (8) 9/181 (5) 11/180 (6)
Del(11q22.3) 105/542 (19) 33/181 (18) 35/181 (19) 37/180 (21)
Trisomy 12 118/542 (22) 40/181 (22) 40/181 (22) 38/180 (21)
None 90/542 (17) 29/181 (16) 32/181 (18) 29/180 (16)
Del(13q14.3) 195/542 (36) 65/181 (36) 65/181 (36) 65/180 (36)
Mutated TP53 — no./total no. (%) 51/510 (10) 16/174 (9) 15/168 (9) 20/168 (12) 0.60
Complex karyotype — no./total no. (%)§ 143/499 (29) 44/166 (27) 39/165 (24) 60/168 (36) 0.04
Unmethylated ZAP70 — no./total no. (%) 287/546 (53) 95/182 (52) 96/182 (53) 96/182 (53) 0.99
Unmutated IgVH gene — no./total no. (%)¶ 218/360 (61) 71/123 (58) 77/122 (63) 70/115 (61) 0.69
*  All P values are for comparisons across all three treatment groups and are two‑sided. P values for continuous variables were calculated with 
the use of the Kruskal–Wallis test, and P values for categorical variables were calculated with the use of the chi‑square test or Fisher’s exact 
test.
†  Eastern Cooperative Oncology Group (ECOG) performance‑status scores range from 0 to 5, with higher scores indicating greater disability.
‡  Central fluorescence in situ hybridization (FISH) analysis was performed with the use of the hierarchical classification method established 
by Döhner et al.20
§  Complex karyotype was defined as the presence of at least three unrelated abnormalities as assessed by central review.
¶  IgVH denotes immunoglobulin variable heavy chain.
Table 1. Characteristics of the Patients at Baseline.
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100
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0
0 6 12 18 24 30 52
Months
No. at Risk
176
178
170
Bendamustine+rituximab
Ibrutinib
Ibrutinib+rituximab
140
165
159
129
154
145
122
147
138
103
136
132
88
120
115
0
0
0
48
11
22
20
42
26
45
40
36
57
78
74
B Subgroup Analysis
A Primary Analysis
0.5000 1.000 4.0002.000
All patients
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
Risk category according to modified Rai stage
Intermediate
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
High
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
Status with regard to del(17p13.1) or del(11q22.3)
Absent
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
Present
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
ZAP70 methylation status
Unmethylated
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
Methylated
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib 
No. of
Patients
Hazard Ratio for Disease Progression
or Death (95% CI)
No. of
EventsSubgroup
0.1250 0.2500
0.37 (0.25–0.56)
0.40 (0.27–0.60)
1.06 (0.66–1.70)
0.44 (0.25–0.78)
0.32 (0.17–0.59)
0.73 (0.36–1.46)
0.33 (0.18–0.60)
0.50 (0.29–0.85)
1.44 (0.75–2.76)
0.44 (0.27–0.72)
0.50 (0.31–0.80)
1.11 (0.65–1.92)
0.26 (0.12–0.56)
0.24 (0.11–0.53)
0.90 (0.35–2.32)
0.19 (0.11–0.35)
0.31 (0.18–0.51)
1.57 (0.80–3.09)
0.81 (0.45–1.48)
0.58 (0.30–1.12)
0.72 (0.36–1.43)
0.0625
365
365
364
167
168
167
198
197
197
263
265
266
102
100
98
191
191
192
173
173
172
105
106
69
53
49
32
52
57
37
70
72
52
35
34
17
61
68
35
43
37
34
Better Worse
Ibrutinib
Bendamustine+
rituximab
Ibrutinib+
rituximab
Bendamustine+Rituximab
Ibrutinib
Ibrutinib+Rituximab
68/176
34/178
32/170
43 (38–NR)
NR
NR
No. of Events/No. of Patients Median (95% CI)
mo
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61% had IgVH-unmutated disease. There was no 
significant difference among the three treatment 
groups with regard to baseline characteristics, 
with the exception of a higher percentage of pa-
tients with a complex karyotype in the ibrutinib-
plus-rituximab group than in the other two treat-
ment groups (P = 0.04).
Of the 524 patients who were enrolled in the 
trial and were determined to have met the eligibil-
ity criteria at screening, 389 patients (74%) con-
sented to undergo the geriatric assessment for the 
correlative analysis, and 369 of those patients 
(95%) completed the assessment before treatment. 
The mean (±SD) score for activities of daily living 
was 13.7±0.8 (range, 9 to 14), and the mean num-
ber of coexisting conditions was 2.5±1.9 (range, 
0 to 14) (Table S3 in the Supplementary Appen-
dix). There was no significant difference among 
the three treatment groups with regard to results 
on the geriatric assessment.
Progression-free Survival and Overall 
Survival
Of the 547 patients who underwent randomiza-
tion, 524 (96%) were determined to have met the 
eligibility criteria at screening and were included 
in the primary analysis. Median progression-free 
survival was reached only with bendamustine plus 
rituximab. The estimated percentage of patients 
with progression-free survival at 2 years was 74% 
(95% confidence interval [CI], 66 to 80) with 
bendamustine plus rituximab, as compared with 
87% (95% CI, 81 to 92) with ibrutinib and 88% 
(95% CI, 81 to 92) with ibrutinib plus rituximab 
(Fig. 2A). The hazard ratio for disease progres-
sion or death was 0.39 (95% CI, 0.26 to 0.58) for 
the comparison of ibrutinib with bendamustine 
plus rituximab (one-sided P<0.001) and 0.38 
(95% CI, 0.25 to 0.59) for the comparison of ibru-
tinib plus rituximab with bendamustine plus 
rituximab (one-sided P<0.001). There was no sig-
nificant difference between the ibrutinib-plus-
rituximab group and the ibrutinib group with 
regard to progression-free survival (hazard ratio, 
1.00; 95% CI, 0.62 to 1.62; one-sided P = 0.49) 
(Fig. 2A). In an intention-to-treat analysis, which 
included all patients who underwent randomiza-
tion, the same conclusions were reached (Fig. S1 
in the Supplementary Appendix).
In analyses of subgroups that were defined ac-
cording to risk factors for CLL, progression-free 
survival was longer with the ibrutinib-containing 
regimens than with bendamustine plus rituximab 
in all risk factor–related subgroups, but the dif-
ference was not significant among patients with 
ZAP70-methylated disease (Fig. 2B). In exploratory 
analyses of subgroups that were defined accord-
ing to cytogenetic factors, there was an interac-
tion between cytogenetics and the effect of treat-
ment on progression-free survival. Progression-free 
survival was longer with the ibrutinib-containing 
regimens than with bendamustine plus rituximab 
in all cytogenetic factor–related subgroups, but 
the difference was greater among patients with 
del(17p13.1) (Fig. S2 in the Supplementary Appen-
dix). In an additional analysis, progression-free 
survival was longer among patients with IgVH-
mutated disease than among those with IgVH-
unmutated disease (hazard ratio, 0.51; 95% CI, 
0.32 to 0.81), but there was no significant inter-
action between IgVH mutation status and the ef-
fect of treatment on progression-free survival. De-
tails regarding this analysis are provided in Tables 
S4 and S5 and Figure S3 in the Supplementary 
Appendix.
At the time of data cutoff, 66 deaths had oc-
curred. The estimated percentage of patients with 
overall survival at 2 years was 95% (95% CI, 91 
to 98) with bendamustine plus rituximab, 90% 
(95% CI, 85 to 94) with ibrutinib, and 94% 
(95% CI, 89 to 97) with ibrutinib plus rituximab. 
There was no significant difference among the 
three treatment groups with regard to overall sur-
vival (P≥0.65 for all pairwise comparisons) (Fig. S4 
in the Supplementary Appendix).
Treatment and Response
At the time of data cutoff, the median follow-up 
was 38 months among the 481 patients who were 
alive. A total of 114 of 182 patients (63%) in the 
Figure 2 (facing page). Primary and Subgroup Analyses 
of Progression-free Survival.
Panel A shows Kaplan–Meier estimates of progres‑
sion‑free survival for each treatment group. The pri‑
mary analysis included all patients who underwent 
randomization and were determined to have met the 
eligibility criteria at screening. Panel B shows hazard 
ratios for disease progression or death at the time of 
data cutoff, according to subgroups that were based 
on risk factors for chronic lymphocytic leukemia. The 
subgroup analysis was performed in the intention‑to‑
treat population. Hazard ratios were calculated with 
univariable Cox proportional‑hazards models. NR de‑
notes not reached.
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ibrutinib group and 117 of 182 patients (64%) in 
the ibrutinib-plus-rituximab group were still re-
ceiving ibrutinib, and 88 of 183 patients (48%) 
in the bendamustine-plus-rituximab group were 
still in remission and undergoing surveillance in 
the trial after completion of treatment. In the 
bendamustine-plus-rituximab group, 67% of the 
patients received six cycles of treatment; the num-
ber of cycles received ranged from one to six, 
with a dose held in 67% of the patients and the 
dose reduced in 37%. In the ibrutinib group, 
the median duration of treatment at the time of 
data cutoff was 32 months (range, 0 to 51), with 
the dose reduced in 13% of the patients. In the 
ibrutinib-plus-rituximab group, the median dura-
tion of ibrutinib treatment at the time of data 
cutoff was 32 months (range, 0 to 52), with the 
dose reduced in 14% of the patients; 92% of the 
patients received all planned doses of rituximab.
The best response was determined by means 
of CT and physical examination in 504 patients 
(92%) and by means of physical examination alone 
in 18 (3%) and was not evaluated in 25 (5%). 
Among all the patients, the response rate was 
lower with bendamustine plus rituximab than 
with the ibrutinib-containing regimens: 81% 
(95% CI, 75 to 87) with bendamustine plus ritux-
imab, as compared with 93% (95% CI, 88 to 96) 
with ibrutinib and 94% (95% CI, 89 to 97) with 
ibrutinib plus rituximab. However, the complete 
response rate was higher with bendamustine plus 
rituximab than with the ibrutinib-containing reg-
imens: 26% (95% CI, 20 to 33), as compared with 
7% (95% CI, 4 to 12) and 12% (95% CI, 8 to 18). 
The percentage of patients with undetectable 
minimal residual disease was significantly higher 
with bendamustine plus rituximab than with the 
ibrutinib-containing regimens: 8% (95% CI, 5 to 
13), as compared with 1% (95% CI, <1 to 3) and 
4% (95% CI, 2 to 8).
Adverse Events
Because adverse events associated with these 
treatments have been reported extensively in the 
literature, we have focused on grade 3 or higher 
adverse events of special interest (Table 2). These 
adverse events are reported regardless of attribu-
tion and include events that occurred during treat-
ment and follow-up, excluding events that occurred 
after crossover. The rate of grade 3, 4, or 5 hema-
tologic adverse events was higher with bendamus-
tine plus rituximab (61%) than with ibrutinib or 
ibrutinib plus rituximab (41% and 39%, respec-
tively), whereas the rate of grade 3, 4, or 5 non-
hematologic adverse events was lower with 
bendamustine plus rituximab (63%) than with the 
ibrutinib-containing regimens (74% with each 
regimen). Infections occurred in all three treat-
ment groups, with respiratory tract infections, 
urinary tract infections, sepsis, and abdominal 
infections being the most common (Table 3, and 
Table S6 in the Supplementary Appendix). Atrial 
fibrillation of any grade occurred in 3% of the 
patients in the bendamustine-plus-rituximab 
group, 17% in the ibrutinib group, and 14% in the 
ibrutinib-plus-rituximab group. Grade 3 or higher 
hypertension occurred in 14%, 29%, and 34%, 
respectively. Summaries of all adverse events are 
provided in Tables S7 through S10 in the Supple-
mentary Appendix.
Death occurred during treatment or within 
30 days after treatment discontinuation in 2 pa-
tients (1%) in the bendamustine-plus-rituximab 
group, 13 (7%) in the ibrutinib group, and 13 (7%) 
in the ibrutinib-plus-rituximab group. Death oc-
curred within the first six cycles of treatment, 
within 30 days after the sixth cycle among those 
who completed six cycles, or within 30 days after 
treatment discontinuation among those who did 
not complete six cycles in 2 patients (1%) in the 
bendamustine-plus-rituximab group, 3 (2%) in the 
ibrutinib group, and 6 (3%) in the ibrutinib-plus-
rituximab group. All causes of death are shown in 
Table S11 in the Supplementary Appendix.
Secondary cancers occurred in 13% of the pa-
tients in the bendamustine-plus-rituximab group 
(excluding events that occurred after crossover), 
13% in the ibrutinib group, and 16% in the ibruti-
nib-plus-rituximab group. Richter’s transformation 
(CLL that evolved into an aggressive lymphoma) 
occurred in 1 patient in the bendamustine-plus-
rituximab group and in 2 patients in the ibrutinib-
plus-rituximab group.
Discussion
In this phase 3 trial, we found that treatment with 
continuous ibrutinib, either alone or in combina-
tion with rituximab, was superior to treatment 
with six cycles of bendamustine plus rituximab 
with regard to progression-free survival. We also 
found that there was no significant difference 
between ibrutinib and ibrutinib plus rituximab 
with regard to progression-free survival. An on-
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Adverse Event
Bendamustine+ 
Rituximab 
(N = 176)
Ibrutinib 
(N = 180)
Ibrutinib+ 
Rituximab 
(N = 181) P Value†
number of patients (percent)
Hematologic
Any <0.001
Grade 3 62 (35) 59 (33) 49 (27)
Grade 4 45 (26) 15 (8) 21 (12)
Anemia 0.09
Grade 3 22 (12) 20 (11) 11 (6)
Grade 4 0 1 (1) 0
Decreased neutrophil count <0.001
Grade 3 39 (22) 15 (8) 20 (11)
Grade 4 32 (18) 12 (7) 19 (10)
Decreased platelet count 0.008
Grade 3 16 (9) 9 (5) 8 (4)
Grade 4 10 (6) 3 (2) 1 (1)
Nonhematologic
Any 0.04
Grade 3 76 (43) 97 (54) 100 (55)
Grade 4 20 (11) 12 (7) 12 (7)
Grade 5 15 (9) 24 (13) 22 (12)
Bleeding‡ 0.46
Grade 3 0 2 (1) 3 (2)
Grade 4 0 1 (1) 1 (1)
Grade 5 0 0 1 (1)
Infection§ 0.62
Grade 3 17 (10) 29 (16) 28 (15)
Grade 4 6 (3) 6 (3) 7 (4)
Grade 5 3 (2) 2 (1) 2 (1)
Febrile neutropenia <0.001
Grade 3 13 (7) 3 (2) 1 (1)
Atrial fibrillation 0.05
Grade 3 5 (3) 15 (8) 10 (6)
Grade 4 0 2 (1) 0
Hypertension <0.001
Grade 3 24 (14) 53 (29) 60 (33)
Grade 4 1 (1) 0 1 (1)
Secondary cancer 0.17
Grade 3 6 (3) 5 (3) 13 (7)
Grade 4 0 1 (1) 1 (1)
Grade 5 1 (1) 4 (2) 1 (1)
Unexplained or unwitnessed death 0.24
Grade 5 2 (1) 7 (4) 4 (2)
*  Shown are adverse events that occurred during treatment or follow‑up, excluding events that occurred after crossover. 
The adverse‑event analysis included all patients who began the assigned treatment.
†  All P values are for comparisons across all three treatment groups and are two‑sided. P values were calculated with the 
use of Fisher’s exact test.
‡  Bleeding events included epistaxis (in three patients), epistaxis and oral hemorrhage (in one patient), and intracranial 
hemorrhage (in four patients, including one with a grade 5 event).
§  Details regarding infections are provided in Table 3.
Table 2. Summary of Grade 3, 4, or 5 Adverse Events.*
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going National Clinical Trials Network (NCTN) 
trial (ClinicalTrials.gov number, NCT02048813) 
aims to evaluate whether treatment with ibrutinib 
plus rituximab is superior to chemoimmunotherapy 
among younger adults.
Improvement in overall survival is the ultimate 
goal of new therapies, and in this analysis, there 
was no significant difference among the three 
treatment groups with regard to overall survival, 
although the follow-up period was short for this 
disease. The rate of grade 5 adverse events was 
higher than expected with the ibrutinib-contain-
ing regimens, although this finding may be due 
to the crossover design and relatively short follow-
up. At the time of this analysis, the most common 
causes of death associated with the ibrutinib-con-
taining regimens, aside from CLL, included un-
explained or unwitnessed death, infection, and 
secondary cancers. It is not clear that these events 
occur more frequently with ibrutinib than with 
bendamustine plus rituximab, but they will be 
monitored closely in long-term follow-up. Both 
atrial and ventricular arrhythmias are known com-
plications of ibrutinib treatment22,23 that have po-
tentially devastating consequences. The mecha-
nism that underlies this association remains 
unclear but may be related to alternative targets 
of ibrutinib, since the incidence of these events 
is lower with the use of more specific BTK in-
hibitors.24,25 The patients who are at highest risk 
for these events and viable treatment options for 
those patients have not yet been identified.
Although this trial was not powered to detect 
differences among subgroups, the results of our 
subgroup analyses raise a few points. First, treat-
ment with the ibrutinib-containing regimens, with 
ibrutinib administered continuously until disease 
progression, appeared to result in longer progres-
sion-free survival than treatment with six cycles 
of bendamustine plus rituximab in all cytogenetic 
Type of Infection
Bendamustine+ 
Rituximab 
(N = 176)
Ibrutinib 
(N = 180)
Ibrutinib+ 
Rituximab 
(N = 181)
number of patients (percent)
Abdominal infection: appendicitis or enterocolitis
Grade 3 0 2 (1) 2 (1)
Other infection or infestation: conjunctivitis, hepatitis 
virus infection, otitis media, or infection in‑
volving the bone, joint, lymph gland, scrotum, 
tooth, skin, or a wound
Grade 3 8 (5) 14 (8) 15 (8)
Respiratory tract infection: bronchial, lung, or upper 
respiratory infection
Grade 3 14 (8) 11 (6) 17 (9)
Grade 5 0 1 (1) 0
Central nervous system infection: encephalitis  
or meningitis
Grade 3 0 1 (1) 1 (1)
Grade 4 0 1 (1) 0
Grade 5 1 (1) 0 0
Sepsis
Grade 4 6 (3) 5 (3) 7 (4)
Grade 5 2 (1) 1 (1) 2 (1)
Urinary tract infection, including bladder infection
Grade 3 3 (2) 4 (2) 5 (3)
*  Shown are infections that occurred during treatment or follow‑up, excluding events that occurred after crossover.
Table 3. Summary of Grade 3, 4, or 5 Infections.*
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factor–related subgroups, as well as among pa-
tients with IgVH-mutated and IgVH-unmutated 
disease. In addition, the presence of a complex 
karyotype, which has previously been shown to 
be an indicator of poor prognosis, did not appear 
to influence ibrutinib-induced progression-free 
survival. Most data regarding complex karyotype 
are from patients with relapsed CLL, so it is pos-
sible that the presence of a complex karyotype is 
biologically different in the absence of DNA-dam-
aging therapy. During long-term follow-up, fur-
ther study of complex karyotype in these patients 
is warranted.
The results of this analysis show the efficacy 
of treatment with continuous ibrutinib among 
patients with untreated CLL, but the results also 
raise the issue of whether indefinite therapy with 
a BTK inhibitor is needed. The significantly lower 
rates of undetectable minimal residual disease 
with the ibrutinib-containing regimens than with 
bendamustine plus rituximab suggest that treat-
ment with single-agent ibrutinib must be contin-
ued indefinitely. Treatments with combined tar-
geted therapies, with the goal of increasing the 
rate of undetectable minimal residual disease and 
ultimately discontinuing treatment, have shown 
promise in early clinical studies26,27 and will be 
evaluated in upcoming NCTN studies (NCT03737981 
and NCT03701282), which may help to address 
this issue.
The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the National 
Institutes of Health.
Supported by the following awards from the National Cancer 
Institute (NCI) of the National Institutes of Health: 
U10CA180821 and U10CA180882, to the Alliance for Clinical 
Trials in Oncology (Alliance); UG1CA189823, to the Alliance 
NCI Community Oncology Research Program Research Base; 
U10CA180790, U10CA180833, U10CA180836, U10CA180850, 
U10CA180857, U10CA180867, P30CA033572, UG1CA189858, 
U10CA180820, U10CA180790, and U10CA180888, to the East-
ern Cooperative Oncology Group and Southwest Oncology 
Group; K23CA178183, to Dr. Woyach; R01CA197870, to Drs. 
Woyach and Byrd; and R35CA197734, to Dr. Byrd. The trial was 
supported in part by Pharmacyclics (a subsidiary of AbbVie).
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
We thank Susan Geyer, Ph.D., for assistance with the initial 
trial design; Samantha Sublett, Eva Hoke, and Luke Wilson for 
assistance with the protocol and data management; and Neil 
Kay and Tait Shanafelt for assistance with the conception and 
design of the trial.
Appendix
The authors’ full names and academic degrees are as follows: Jennifer A. Woyach, M.D., Amy S. Ruppert, Ph.D., Nyla A. Heerema, 
Ph.D., Weiqiang Zhao, M.D., Allison M. Booth, M.S., Wei Ding, M.B., B.S., Ph.D., Nancy L. Bartlett, M.D., Danielle M. Brander, M.D., 
Paul M. Barr, M.D., Kerry A. Rogers, M.D., Sameer A. Parikh, M.B., B.S., Steven Coutre, M.D., Arti Hurria, M.D., Jennifer R. Brown, 
M.D., Ph.D., Gerard Lozanski, M.D., James S. Blachly, M.D., Hatice G. Ozer, Ph.D., Brittny Major-Elechi, M.S., Briant Fruth, B.S., 
Sreenivasa Nattam, M.D., Richard A. Larson, M.D., Harry Erba, M.D., Ph.D., Mark Litzow, M.D., Carolyn Owen, M.D., Ph.D., Charles 
Kuzma, M.D., Jeremy S. Abramson, M.D., Richard F. Little, M.D., Scott E. Smith, M.D., Ph.D., Richard M. Stone, M.D., Sumithra J. 
Mandrekar, Ph.D., and John C. Byrd, M.D.
The authors’ affiliations are as follows: Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., 
K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., 
S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University 
Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) — both in North Carolina; 
the University of Rochester Medical Center, Rochester, NY (P.M.B.); Stanford University School of Medicine, Stanford (S.C.), and the 
City of Hope Comprehensive Cancer Center, Duarte (A.H.) — both in California; Dana–Farber Partners CancerCare (J.R.B., R.M.S.) and 
the Massachusetts General Hospital Cancer Center (J.S.A.) — both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and Loyola University Chicago (S.E.S.) — both in Chi-
cago; the University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer Treatment and Di-
agnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
References
1. Woyach JA, Bojnik E, Ruppert AS, et al. 
Bruton’s tyrosine kinase (BTK) function 
is important to the development and ex-
pansion of chronic lymphocytic leukemia 
(CLL). Blood 2014; 123: 1207-13.
2. Kil LP, de Bruijn MJ, van Hulst JA, 
Langerak AW, Yuvaraj S, Hendriks RW. 
Bruton’s tyrosine kinase mediated signal-
ing enhances leukemogenesis in a mouse 
model for chronic lymphocytic leukemia. 
Am J Blood Res 2013; 3: 71-83.
3. Goede V, Fischer K, Busch R, et al. 
Obinutuzumab plus chlorambucil in pa-
tients with CLL and coexisting conditions. 
N Engl J Med 2014; 370: 1101-10.
4. Eichhorst B, Fink AM, Bahlo J, et al. 
First-line chemoimmunotherapy with 
bendamustine and rituximab versus fluda-
rabine, cyclophosphamide, and rituximab 
in patients with advanced chronic lym-
phocytic leukaemia (CLL10): an interna-
tional, open-label, randomised, phase 3, 
non-inferiority trial. Lancet Oncol 2016; 
17: 928-42.
5. Herman SE, Gordon AL, Hertlein E, 
et al. Bruton tyrosine kinase represents a 
promising therapeutic target for treat-
ment of chronic lymphocytic leukemia 
and is effectively targeted by PCI-32765. 
Blood 2011; 117: 6287-96.
6. Herman SE, Mustafa RZ, Gyamfi JA, 
et al. Ibrutinib inhibits BCR and NF-κB 
signaling and reduces tumor proliferation 
in tissue-resident cells of patients with 
CLL. Blood 2014; 123: 3286-95.
7. Herman SE, Mustafa RZ, Jones J, 
Wong DH, Farooqui M, Wiestner A. Treat-
ment with ibrutinib inhibits BTK- and 
VLA-4-dependent adhesion of chronic 
The New England Journal of Medicine 
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;26 nejm.org December 27, 20182528
Ibrutinib Regimens vs. Chemoimmunother apy in CLL
lymphocytic leukemia cells in vivo. Clin 
Cancer Res 2015; 21: 4642-51.
8. Woyach JA, Smucker K, Smith LL, et 
al. Prolonged lymphocytosis during ibru-
tinib therapy is associated with distinct 
molecular characteristics and does not 
indicate a suboptimal response to ther-
apy. Blood 2014; 123: 1810-7.
9. de Gorter DJ, Beuling EA, Kersse-
boom R, et al. Bruton’s tyrosine kinase 
and phospholipase Cgamma2 mediate che-
mokine-controlled B cell migration and 
homing. Immunity 2007; 26: 93-104.
10. de Rooij MF, Kuil A, Geest CR, et al. 
The clinically active BTK inhibitor 
PCI-32765 targets B-cell receptor- and 
chemokine-controlled adhesion and mi-
gration in chronic lymphocytic leukemia. 
Blood 2012; 119: 2590-4.
11. Ponader S, Chen SS, Buggy JJ, et al. 
The Bruton tyrosine kinase inhibitor 
PCI-32765 thwarts chronic lymphocytic leu-
kemia cell survival and tissue homing in 
vitro and in vivo. Blood 2012; 119: 1182-9.
12. O’Brien S, Furman RR, Coutre S, et al. 
Single-agent ibrutinib in treatment-naïve 
and relapsed/refractory chronic lympho-
cytic leukemia: a 5-year experience. Blood 
2018; 131: 1910-9.
13. Barr PM, Robak T, Owen C, et al. Sus-
tained efficacy and detailed clinical fol-
low-up of first-line ibrutinib treatment in 
older patients with chronic lymphocytic 
leukemia: extended phase 3 results from 
RESONATE-2. Haematologica 2018; 103: 
1502-10.
14. Burger JA, Tedeschi A, Barr PM, et al. 
Ibrutinib as initial therapy for patients with 
chronic lymphocytic leukemia. N Engl J 
Med 2015; 373: 2425-37.
15. Hallek M, Fischer K, Fingerle-Rowson 
G, et al. Addition of rituximab to fludara-
bine and cyclophosphamide in patients 
with chronic lymphocytic leukaemia: 
a randomised, open-label, phase 3 trial. 
Lancet 2010; 376: 1164-74.
16. Hallek M, Cheson BD, Catovsky D, et al. 
Guidelines for the diagnosis and treatment 
of chronic lymphocytic leukemia: a report 
from the International Workshop on Chron-
ic Lymphocytic Leukemia updating the 
National Cancer Institute-Working Group 
1996 guidelines. Blood 2008; 111: 5446-56.
17. Claus R, Lucas DM, Stilgenbauer S, et 
al. Quantitative DNA methylation analysis 
identifies a single CpG dinucleotide im-
portant for ZAP-70 expression and predic-
tive of prognosis in chronic lymphocytic 
leukemia. J Clin Oncol 2012; 30: 2483-91.
18. Rai KR. A critical analysis of staging 
in CLL. In: Gale RP, Rai KR, eds. Chronic 
lymphocytic leukemia: recent progression 
and future directions. New York: Liss, 
1987: 253-64.
19. Pocock SJ, Simon R. Sequential treat-
ment assignment with balancing for prog-
nostic factors in the controlled clinical 
trial. Biometrics 1975; 31: 103-15.
20. Döhner H, Stilgenbauer S, Benner A, 
et al. Genomic aberrations and survival in 
chronic lymphocytic leukemia. N Engl J 
Med 2000; 343: 1910-6.
21. Haferlach C, Dicker F, Schnittger S, 
Kern W, Haferlach T. Comprehensive ge-
netic characterization of CLL: a study on 
506 cases analysed with chromosome 
banding analysis, interphase FISH, IgV(H) 
status and immunophenotyping. Leuke-
mia 2007; 21: 2442-51.
22. Leong DP, Caron F, Hillis C, et al. The 
risk of atrial fibrillation with ibrutinib 
use: a systematic review and meta-analysis. 
Blood 2016; 128: 138-40.
23. Guha A, Derbala MH, Zhao Q, et al. 
Ventricular arrhythmias following ibruti-
nib initiation for lymphoid malignancies. 
J Am Coll Cardiol 2018; 72: 697-8.
24. Byrd JC, Harrington B, O’Brien S, et al. 
Acalabrutinib (ACP-196) in relapsed chronic 
lymphocytic leukemia. N Engl J Med 2016; 
374: 323-32.
25. Tam C, Grigg AP, Opat S, et al. The 
BTK inhibitor, Bgb-3111, is safe, tolerable, 
and highly active in patients with relapsed/
refractory B-cell malignancies: initial re-
port of a phase 1 first-in-human trial. 
Blood 2015; 126: 832. abstract.
26. Rogers K, Huang Y, Stark A, et al. Ini-
tial results of the phase 2 treatment naive 
cohort in a phase 1b/2 study of obinutuzu-
mab, ibrutinib, and venetoclax in chronic 
lymphocytic leukemia. Blood 2017; 130: 431. 
abstract.
27. Seymour JF, Kipps TJ, Eichhorst B, 
et al. Venetoclax-rituximab in relapsed or 
refractory chronic lymphocytic leukemia. 
N Engl J Med 2018; 378: 1107-20.
Copyright © 2018 Massachusetts Medical Society.
receive immediate notification when an article  
is published online first
To be notified by email when Journal articles  
are published online first, sign up at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
